Cost-Effectiveness of Recombinant Zoster Vaccine (Shingrix) in U.S. Adults Aged ≥50 Years
Listen to this summary
The authors aimed to evaluate the cost-effectiveness of the recombinant zoster vaccine (Shingrix) in U.S. adults aged 50 years and older, considering new evidence on its long-term efficacy and pricing. Their analysis revealed that the vaccine is cost-effective for individuals aged 60 and older, with an optimal vaccination age identified around 54 years. The study underscores the importance of ongoing assessments of the vaccine's long-term protection and the potential need for booster doses.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from The American journal of medicine
View all →Jun 24, 2026 · The American journal of medicine
Chronic Inflammatory Diseases and Survival among Patients with Pancreatic Cancer in the U.S. Military Health System
Jun 24, 2026 · The American journal of medicine
Risk of Infection-Related Hospitalization Is More Than Doubled in Cushing's Syndrome vs Matched Controls
Jun 24, 2026 · The American journal of medicine
Practice Changing Updates in Perioperative Medicine Literature 2025. A Systematic Review
Jun 23, 2026 · The American journal of medicine
Assessment of in-hospital mortality in patients with upper gastrointestinal bleeding on antithrombotic treatment: A Systematic Review and Meta-Analysis
Jun 22, 2026 · The American journal of medicine
Night-Shift Intensity, Duration, Cardiovascular Susceptibility and Incident Cardiovascular Disease: UK Biobank Study
Jun 22, 2026 · The American journal of medicine
Medications for alcohol use disorder in Alcohol-Associated Liver Disease: The Role of Gastroenterologist and Hepatologist in Treatment and Outcomes
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Journal of addiction medicine
Medicaid Prior Authorization and Discontinuation of Buprenorphine
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
